GCM
CYTK icon

Graham Capital Management’s Cytokinetics CYTK Stock Holding History

Graham Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,414
Closed -$291K – 1309
2026
Q1 		$291K Buy
+4,414
New +$281K 0.01% 829
2025
Q2 		– Sell
-15,991
Closed -$643K – 1350
2025
Q1 		$643K Buy
+15,991
New +$735K 0.01% 706
2024
Q3 		– Sell
-7,699
Closed -$417K – 1142
2024
Q2 		$417K Buy
7,699
+4,386
+132% +$265K 0.01% 637
2024
Q1 		$232K Buy
+3,313
New +$256K ﹤0.01% 862

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's CYTK Position: Q2 2026 in Review

Graham Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 4,414 shares — an estimated $291K sold.

Graham Capital Management first reported a position in CYTK in Q1 2024 and held it in 4 quarters. The position peaked at $643K in Q1 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Graham Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 4,414 Cytokinetics shares in Q2 2026, an estimated $291K.
  • Graham Capital Management first reported a position in Cytokinetics in Q1 2024 and held it in 4 quarters.
  • Graham Capital Management's Cytokinetics position peaked at $643K in Q1 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.